Oasmia announces topline results from head-to-head comparison study of Paclical and Abraxane

Preliminary study findings show that water soluble and solvent free Paclical^®, and US-market approved Abraxane® have nearly identical concentration curves of both total and unbound paclitaxel following intravenous infusion of 260mg/m² suggesting the same efficacy of the two drugs.

Oasmia Pharmaceutical AB, developer of a new generation of drugs within human and veterinary oncology, announced today the topline findings from a head-to-head comparison study of its lead human cancer product candidate Paclical® and Celgene's Abraxane®, which show similar pharmacokinetic (PK) profiles of the two products. The study was conducted in women with metastatic breast cancer.

"We believe our technology is superior to Abraxane® because it increases the solubility of paclitaxel in water," commented Margareta Eriksson, Vice President of Clinical Development at Oasmia Pharmaceutical. "The benefits of using our treatment over those currently available on the market are simple: Paclical® enables higher doses, shortens infusion time, eliminates the need for pre-medication and improves the safety profile for patients."

SOURCE Oasmia Pharmaceutical AB